Literature DB >> 2569932

Atypical multidrug resistance in a therapy-induced drug-resistant human leukemia cell line (LALW-2): resistance to Vinca alkaloids independent of P-glycoprotein.

M Haber1, M D Norris, M Kavallaris, D R Bell, R A Davey, L White, B W Stewart.   

Abstract

Near diploid leukemic T-cells (LALW-2), exposed to cytotoxic drugs only as a consequence of therapy administered to the donor patient, have been maintained by serial xenograft in nude mice. In comparison with the leukemic line CCRF-CEM, using a growth inhibition assay, LALW-2 cells were resistant to Vinca alkaloids and actinomycin D (relative resistance, 200-fold or more), were slightly resistant to Adriamycin (relative resistance, 4-fold), and showed no resistance to daunorubicin or teniposide. By comparison, a vincristine-resistant CEM subline developed in our laboratory (CEM/VCR R) was resistant to all these agents by at least 30-fold. The VCR R subline served as a positive control, confirming the previously reported correlation between multidrug resistance and amplification of the P-glycoprotein gene. Comparison of CEM, CEM/VCR R, and LALW-2 cells establish that the P-glycoprotein gene was not amplified or overexpressed in the LALW-2 cells; neither could the gene product be detected by immunoblotting in extracts from these cells. The LALW-2 cells were further distinguished from CEM/VCR R cells due to the lack of increased vincristine efflux by the xenografted cells, an effect readily demonstrable in the CEM/VCR R cells. However, although LALW-2 cells efflux vincristine at the same rate as CCRF-CEM cells, the xenografted cells exhibited a reduced rate of vincristine accumulation. Uptake of daunorubicin by LALW-2 cells was not distinguished from that by CEM cells, consistent with similar 50% inhibitory dose levels for this drug in both cell populations, and differentiating both from CEM/VCR R cells. Thus, clinical resistance in this case appears to be an "atypical" form of multidrug resistance specifically distinguished by resistance to Vinca alkaloids and actinomycin D occurring in the absence of increased amounts of P-glycoprotein and manifesting decreased drug uptake.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2569932

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  A novel synthetic 1,3-phenyl bis-thiourea compound targets microtubule polymerization to cause cancer cell death.

Authors:  Jennifer C Shing; Jae Won Choi; Robert Chapman; Mark A Schroeder; Jann N Sarkaria; Abdul Fauq; Richard J Bram
Journal:  Cancer Biol Ther       Date:  2014-04-22       Impact factor: 4.742

2.  The Uptake of (+)-S- and (-)-R-Abscisic Acid by Suspension Culture Cells of Hopbush (Dodonaea viscosa).

Authors:  M L Windsor; B V Milborrow; I J McFarlane
Journal:  Plant Physiol       Date:  1992-09       Impact factor: 8.340

Review 3.  Chemotherapeutic drug resistance in the management of head and neck cancer.

Authors:  H Bier
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

Review 4.  Preclinical and clinical pharmacology of vinca alkaloids.

Authors:  X J Zhou; R Rahmani
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 5.  Non-P-glycoprotein multidrug resistance in cell lines which are defective in the cellular accumulation of drug.

Authors:  M S Center
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

6.  Identification of a human endothelial cell activation antigen that is co-expressed by germinal follicle centre B lymphocytes.

Authors:  S S To; T Magoulas; E Nicholson; L Schrieber
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

7.  In vitro analysis of drug resistance in tumor cells from patients with acute myelocytic leukemia.

Authors:  J Kristensen; B Jonsson; C Sundström; P Nygren; R Larsson
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

8.  Chemomodulation of drugs involved in multidrug resistance in chronic lymphatic leukemia of the B-cell type.

Authors:  A Reichle; H Diddens; F Altmayr; J Rastetter; R Andreesen
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 9.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

10.  Small molecule inhibitors of the mitochondrial ClpXP protease possess cytostatic potential and re-sensitize chemo-resistant cancers.

Authors:  Martina Meßner; Melanie M Mandl; Mathias W Hackl; Till Reinhardt; Maximilian A Ardelt; Karolina Szczepanowska; Julian E Frädrich; Jens Waschke; Irmela Jeremias; Anja Fux; Matthias Stahl; Angelika M Vollmar; Stephan A Sieber; Johanna Pachmayr
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.